BioLASCO Taiwan Valuation

Is 6662 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 6662 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 6662 (NT$35.5) is trading above our estimate of fair value (NT$15.04)

Significantly Below Fair Value: 6662 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 6662?

Key metric: As 6662 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 6662. This is calculated by dividing 6662's market cap by their current earnings.
What is 6662's PE Ratio?
PE Ratio	21.4x
Earnings	NT$42.50m
Market Cap	NT$909.23m

6662 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	3x
Enterprise Value/EBITDA	15x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does 6662's PE Ratio compare to its peers?

The above table shows the PE ratio for 6662 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	20.7x
4133 Abnova (Taiwan)	26.5x	n/a	NT$1.7b
6986 HeXun Biosciences	26.1x	n/a	NT$3.2b
6848 RBC Bioscience	15x	n/a	NT$258.9m
4102 Yung Zip Chemical Ind	15.2x	n/a	NT$1.3b
6662 BioLASCO Taiwan	21.4x	n/a	NT$909.2m

Price-To-Earnings vs Peers: 6662 is expensive based on its Price-To-Earnings Ratio (21.4x) compared to the peer average (20.7x).

Price to Earnings Ratio vs Industry

How does 6662's PE Ratio compare vs other companies in the Asian Life Sciences Industry?

1 Company	Price / Earnings	Estimated Growth	Market Cap

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: 6662 is good value based on its Price-To-Earnings Ratio (21.4x) compared to the Asian Life Sciences industry average (30.3x).

Price to Earnings Ratio vs Fair Ratio

What is 6662's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

6662 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	21.4x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 6662's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

RBC Bioscience

NT$258.9m

Researches, develops, manufactures, and sells reagents and devices for life science and molecular diagnosis in Europe, the United States, Asia, Taiwan, Africa, and Australia.

6848

NT$19.95

-2.2%

32.6%

YungShin Global Holding

NT$14.3b

Through its subsidiaries, invests in, manufactures, and sells medicines, animal drugs, agricultural chemicals, industrial medicines, and cosmetics in Taiwan, Mainland China, Japan, and the United States.

3705

NT$53.50

-2.4%

18.1%

Cenra

NT$6.0b

Engages in the research and development, manufacture, and sale of generic pharmaceutical and healthcare products for humans and animals.

1701

NT$21.15

-8.8%